Skip to main content

Table 7 Presence of allele *0201 at locus HLA-A by clinical activity status: all response-evaluable patients.

From: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Clinical Activity Status

n (%)

 

Allele Absent

Allele Present

Allele Status Unknown

Total

Benefit

4 (33.3)

8 (66.7)

0 (0.0)

12 (16.9)

CR or PR

3 (37.5)

5 (62.5)

0 (0.0)

8 (11.3)

Prolonged SD

1 (25.0)

3 (75.0)

0 (0.0)

4 (5.6)

Non-benefit

21 (45.7)

25 (54.3)

3 (6.1)

49 (69.0)

Unknown

6 (66.7)

3 (33.3)

1 (10.0)

10 (14.1)

Total

31 (46.3)

36 (53.7)

4 (5.6)

71 (100.0)

  1. Denominator for percents in columns "Allele Absent" and "Allele Present" is number of patients in row who have a known allele status.
  2. Denominator for percents in column "Allele Status Unknown" is total number of patients in row.
  3. Denominator for percents in column "Total" is number of response-evaluable patients.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us